guest ::
| Home > Publications database > Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d -Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species > print |
| Home > Publications database > Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d -Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species > print |
| 001 | 821057 | ||
| 005 | 20210129224736.0 | ||
| 024 | 7 | _ | |a 10.1021/acschemneuro.6b00047 |2 doi |
| 024 | 7 | _ | |a WOS:000381717300009 |2 WOS |
| 024 | 7 | _ | |a altmetric:8467763 |2 altmetric |
| 024 | 7 | _ | |a pmid:27240424 |2 pmid |
| 037 | _ | _ | |a FZJ-2016-06301 |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Ziehm, Tamar |0 P:(DE-Juel1)162487 |b 0 |u fzj |
| 245 | _ | _ | |a Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d -Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species |
| 260 | _ | _ | |a Washington, DC |c 2016 |b ACS Publ. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1479297656_29809 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common type of dementia. Until now, there is no curative therapy available. Previously, we selected the amyloid-beta (Aβ) targeting peptide D3 consisting of 12 D-enantiomeric amino acid residues by mirror image phage display as a potential drug candidate for the treatment of AD. In the current approach, we investigated the optimization potential of the net charge was investigated and second, cyclization was introduced which is a well-known tool for the optimization of peptides for enhanced target affinity. Following this strategy, three D3 derivatives in addition to D3COOH were designed: C-terminally amidated linear D3 (D3CONH2), cyclic D3 (cD3), and cyclic D3 with an additional arginine residue (cD3r) to maintain the net charge of linear D3CONH2. These four compounds were compared to each other according to their binding affinities to Aβ(1−42), their efficacy to eliminate cytotoxic oligomers, and consequently their potency to neutralize Aβ(1−42) oligomer induced neurotoxicity. D3CONH2 and cD3r versions with equally increased net charge showed superior properties over D3COOH and cD3, respectively. The cyclic versions showed superior properties compared to their linear version with equal net charge, suggesting cD3r to be the most efficient compound among these four. Indeed, treatment of the transgenic AD mouse model Tg-SwDI with cD3r significantly enhanced spatial memory and cognition of these animals as revealed by water maze performance. Therefore, charge increase and cyclization imply suitable modification steps for an optimization approach of the Aβ targeting compound D3. |
| 536 | _ | _ | |a 553 - Physical Basis of Diseases (POF3-553) |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Brener, Oleksandr |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a van Groen, Thomas |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Kadish, Inga |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Frenzel, Daniel |0 P:(DE-Juel1)145441 |b 4 |
| 700 | 1 | _ | |a Tusche, Markus |0 P:(DE-Juel1)131709 |b 5 |u fzj |
| 700 | 1 | _ | |a Kutzsche, Janine |0 P:(DE-Juel1)159137 |b 6 |u fzj |
| 700 | 1 | _ | |a Reiß, Kerstin |0 P:(DE-Juel1)161220 |b 7 |
| 700 | 1 | _ | |a Gremer, Lothar |0 P:(DE-Juel1)145165 |b 8 |u fzj |
| 700 | 1 | _ | |a Nagel-Steger, Luitgard |0 P:(DE-Juel1)162443 |b 9 |u fzj |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 10 |e Corresponding author |u fzj |
| 773 | _ | _ | |a 10.1021/acschemneuro.6b00047 |g Vol. 7, no. 8, p. 1088 - 1096 |0 PERI:(DE-600)2528493-9 |n 8 |p 1088 - 1096 |t ACS chemical neuroscience |v 7 |y 2016 |x 1948-7193 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/821057/files/acschemneuro.6b00047.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:821057 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)162487 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)131709 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)159137 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)145165 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)162443 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 10 |6 P:(DE-Juel1)132029 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ACS CHEM NEUROSCI : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a No Authors Fulltext |0 StatID:(DE-HGF)0550 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|